“I have a heart like a motor, and I can take more than you.” – Gerber, Max S. Introduction. My Heart vs. the Real World: Children with Heart Disease, in Photographs & Interviews. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 2008. 2. Print.
Cardiac protection in youth cancer patients is something that many have focused their trials on for awhile now. Pediatric cardiologist Gonzalo Wallis, MD, from Charlotte North Carolina has been working on a new trial testing the effects of Dexrazoxane, also known as Zinecard or Totect, can have on protecting these young hearts while they are undergoing chemotherapy sessions.
Dexrazoxane is a cardioprotective drug that can minimize doxorubicin during chemotherapy treatments. The hope is that is can also minimize cardiac failure later on after the treatments have been successful in these children’s lives.
This study at the Carolinas HealthCare System’s Sanger Heart & Vascular Institute has been rather small, leading to minimal results thus far. However, they would love to grow the size of these trials as well as see the results in twenty to thirty years when these children have grown and lived out many more years of their lives after treatment.
Feel free to watch this video of Gonzalo Wallis, MD explain further…